Opsona Therapeutics

DUBLIN, May 6, 2011 - Opsona Therapeutics, a drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases announced that it will receive EUR5.9million, one of the largest grants ever awarded by the European Union FP7 Health, Program, to lead a European consortium of research and clinical groups (MABSOT*) in the advancement of clinical trials for its lead drug candidate OPN-305 in solid organ transplantation.